

## Certificate of Analysis

Catalog Number	BP13799
Product Name	Delcasertib

## Physical and Chemical Properties

Synonyms	BMS-875944, KAI-9803
CAS No.	949100-39-4
Chemical Formula	C <sub>120</sub> H <sub>199</sub> N <sub>45</sub> O <sub>34</sub> S <sub>2</sub>
Molecular Weight	2880.31
Solubility	DMSO: 99 mg/mL(34.37 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	Sequence 1: Cys-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg; Sequence 1': Ser-Phe-Asn-Ser-Tyr-Glu-Leu-Gly-Ser-Leu (Disulfide bridge: Cys <sub>1</sub> -Cys <sub>1'</sub> )

## Product Information

Description	Delcasertib is a potent and selective inhibitor of $\delta$ -protein kinase C ( $\delta$ PKC).
-------------	--

In vitro	Delcasertib is composed of a selective $\delta$ -protein kinase C ( $\delta$ PKC) inhibitor peptide derived from the $\delta$ V1-1 portion of $\delta$ PKC (termed "cargo peptide"), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47-57; termed "carrier peptide") via a disulfide bond.
In vivo	KAI-9803 ameliorates pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Delcasertib has an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Delcasertib administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction. $^{14}\text{C}$ -KAI-9803 is rapidly delivered to many tissues, including the heart ( $1.21\text{ }\mu\text{g eq/g}$ tissue), while being quickly cleared from the systemic circulation. The distribution of Delcasertib to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47-57.

## Analytical Data

HPLC	Shows Min >99% purity
H-NMR	Consistent with structure
Stability and Solubility Advice	Information on product stability, especially in solution, has rarely been reported and in most cases we can only provide a general guideline. We recommend that once the stock solution has been prepared, it be stored in equal quantities in sealed vials and used within 1 month. Avoid repeated freezing and thawing cycles. Storage conditions for some special products should be referred to their storage details.

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022